Datasheet is currently unavailable. Try again or CONTACT US
Ubiquitin Hydrolase (UCHL1) Antibody
Chicken Polyclonal
1 References
200-901-E52
100 µL
Liquid
WB, IF, Multiplex, Other
Human, Mouse, Rat, Bovine
Chicken
Shipping info:
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Product Details
Anti-Ubiquitin Hydrolase (UCHL1) (Chicken) Antibody - 200-901-E52
UCH-L1, Neuron cytoplasmic protein 9.5, PGP 9.5, Ubiquitin thioesterase L1
Chicken
Polyclonal
IgY
Target Details
UCHL1 - View All UCHL1 Products
Human, Mouse, Rat, Bovine
Recombinant Protein
Anti-UCHL1 Antibody was produced in chicken by repeated immunizations with recombinant full length human UCHL1 extensively purified from E. coli.
Anti-UCHL1 antibody is directed against human UCHL1 proteins. The antibody was purified from chicken eggs as an IgY fraction. Reactivity is expected from human, mouse, rat and bovine. Cross reactivity with UCHL1 from other species has not been determined. However, expect reactivity against most mammalian species based on high sequence homology.
P09936 - UniProtKB
Application Details
IF, WB, Multiplex
Other
- View References
Anti-Ubiquitin Hydrolase antibody is tested for use in Western Blotting and IF. Specific conditions for reactivity should be optimized by the end user. Expect a band of approximately 24 kDa in size corresponding to the UCHL1 proteins in Western blots in the appropriate cell lysate or extract.
Formulation
Titrated value sufficient to run approximately 10 mini blots.
0.01 M Sodium Phosphate, 0.15 M Sodium Chloride, pH 7.2
0.01% (w/v) Sodium Azide
None
Shipping & Handling
Dry Ice
Store vial at -20° C prior to opening. This product is stable at 4° C as an undiluted liquid. For extended storage, aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Dilute only prior to immediate use.
Expiration date is one (1) year from date of receipt.
UCHL1 antibody recognizes Ubiquitin C-terminal hydrolase 1 (UCHL1) which is also known as ubiquitin carboxyl esterase L1, ubiquitin thiolesterase, neuron-specific protein PGP9.5 and Park5. It was originally identified as a major component of the neuronal cytoplasm from 2-dimensional gel analysis of brain tissues, and was given the name PGP9.5. It was later found that ubiquitin C-terminal hydrolase enzyme activity was associated with the PGP9.5 protein. The ubiquitin C-terminal hydrolases cleave ubiquitin from other molecules. Regulation of the ubiquitin pathway is very important and many disease states are associated with defects in this pathway. Genetic knockout of UCHL1 in mice results in a motor neuron degeneration similar to the spontaneous gracile axonal dystrophy (gad) mutant mice. Point mutations in the UCHL1 gene are associated with some forms of human Parkinson's disease. Since UCHL1 is heavily expressed in neurons, it is released in large amounts following injury or degeneration, so the detection of UCHL1 in CSF and other bodily fluids can be used as a biomarker. Therefore, UCHL1 antibody is ideal for investigators involved in neuronal disorders and, more generally in Neuroscience.
Guseva D et al. (2014). Over-expression of Oct4 and Sox2 transcription factors enhances differentiation of human umbilical cord blood cells in vivo. Biochem Biophys Res Commun.
Applications
IF, Confocal Microscopy
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
